Management of Acute ILD Exacerbation (AE-IPF): Does Rituximab Provide Beneficial Effects for IPF Patients? What Is the Efficacy of Autoantibody Reduction Therapies? | VuMedi

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

10 seconds

Playback speed

Advanced Lung Disease Conference 2020

Management of Acute ILD Exacerbation (AE-IPF): Does Rituximab Provide Beneficial Effects for IPF Patients? What Is the Efficacy of Autoantibody Reduction Therapies?

By Advanced Lung Disease Conference 2020 FEATURING Steven Duncan

By Advanced Lung Disease Conference 2020 FEATURING Steven Duncan

674 views

February 2, 2021

Comments 1

Login to view comments. Click here to Login